Here are the 10-K annual reports from ImageneBio, Inc. (IMA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc., formerly Ikena Oncology, completed its merger with Legacy Inmagene and now operates as a clinical-stage biopharmaceutical company focused on immune and inflammatory diseases. The business centers on IMG-007, a non-depleting anti-OX40 antibody initially developed for moderate-to-severe atopic dermatitis.
Early Phase 1b/2a data in atopic dermatitis showed meaningful and durable responses, including EASI‑75 rates of 54% and EASI‑90 rates of 31% at Week 16 after a four-week IV dosing period, with sustained biomarker improvements across Th1, Th2 and Th17 pathways. A multi-country Phase 2b subcutaneous dose-finding trial in atopic dermatitis is under way, with topline data expected in 2027.
The company sees IMG-007 as a potential “pipeline within a product,” with exploratory work in alopecia areata and possible future indications such as asthma, rheumatoid arthritis and hidradenitis suppurativa. However, the business remains entirely dependent on IMG-007’s success, expects significant ongoing losses, requires substantial additional funding, faces intense competition from established biologics and JAK inhibitors, and has disclosed a material weakness in internal controls over financial reporting.